AAAAAA
Results: 1-25/47
Authors:
WIERNIK PH
MOORE DF
BENNETT JM
VOGL SE
HARRIS JE
LUGER S
OKEN MM
GLICK JH
Citation: Ph. Wiernik et al., PHASE-II STUDY OF MITOGUAZONE, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE FOR PATIENTS WITH DIFFUSE HISTOLOGIC SUBTYPES OF NON-HODGKINS-LYMPHOMA - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY (PE481), Leukemia & lymphoma, 30(5-6), 1998, pp. 601-607
Authors:
WIERNIK PH
PHILLIPS V
CAMACHO FJ
OKEN MM
OCONNELL MJ
Citation: Ph. Wiernik et al., METHYLGUAZONE, VINDESINE AND CISPLATIN FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MALIGNANT-LYMPHOMA - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY (PA482), Leukemia & lymphoma, 30(5-6), 1998, pp. 619-624
Authors:
FRIEDENBERG WR
KELLER A
YOUNG J
OKEN MM
Citation: Wr. Friedenberg et al., INFUSIONAL CHEMOTHERAPY FOR NON-HODGKINS-LYMPHOMA, Cancer investigation, 16(7), 1998, pp. 544-546
Authors:
GLICK JH
YOUNG ML
HARRINGTON D
SCHILSKY RL
BECK T
NEIMAN R
FISHER RI
PETERSON BA
OKEN MM
Citation: Jh. Glick et al., MOPP ABV HYBRID CHEMOTHERAPY FOR ADVANCED HODGKINS-DISEASE SIGNIFICANTLY IMPROVES FAILURE-FREE AND OVERALL SURVIVAL - THE 8-YEAR RESULTS OFTHE INTERGROUP TRIAL/, Journal of clinical oncology, 16(1), 1998, pp. 19-26
Authors:
KAY NE
LEONG T
BONE N
KYLE RA
GREIPP PR
VANNESS B
OKEN MM
Citation: Ne. Kay et al., T-HELPER PHENOTYPES IN THE BLOOD OF MYELOMA PATIENTS ON ECOG PHASE-III TRIALS E9486 E3A93/, British Journal of Haematology, 100(3), 1998, pp. 459-463
Authors:
GREIPP PR
LEONG T
BENNETT JM
GAILLARD JP
KLEIN B
STEWART JA
OKEN MM
KAY NE
VANNESS B
KYLE RA
Citation: Pr. Greipp et al., PLASMABLASTIC MORPHOLOGY - AN INDEPENDENT PROGNOSTIC FACTOR WITH CLINICAL AND LABORATORY CORRELATES - EASTERN-COOPERATIVE-ONCOLOGY-GROUP (ECOG) MYELOMA TRIAL E9486 REPORT BY THE ECOG MYELOMA LABORATORY GROUP, Blood, 91(7), 1998, pp. 2501-2507
Authors:
WINTER JN
ANDERSEN J
REED JC
KRAJEWSKI S
VARIAKOJIS D
BAUER KD
FISHER RI
GORDON LI
OKEN MM
JIANG SW
JEFFRIES D
DOMER P
Citation: Jn. Winter et al., BCL-2 EXPRESSION CORRELATES WITH LOWER PROLIFERATIVE ACTIVITY IN THE INTERMEDIATE-GRADE AND HIGH-GRADE NON-HODGKINS-LYMPHOMAS - AN EASTERN CCOOPERATIVE ONCOLOGY GROUP AND SOUTHWEST-ONCOLOGY-GROUP COOPERATIVE LABORATORY STUDY, Blood, 91(4), 1998, pp. 1391-1398
Authors:
KIRKWOOD JM
BRYANT J
SCHILLER JH
OKEN MM
BORDEN EC
WHITESIDE TL
Citation: Jm. Kirkwood et al., IMMUNOMODULATORY FUNCTION OF INTERFERON-GAMMA IN PATIENTS WITH METASTATIC MELANOMA - RESULTS OF A PHASE II-B TRIAL IN SUBJECTS WITH METASTATIC MELANOMA, ECOG STUDY E-4987, Journal of immunotherapy with emphasis on tumor immunology, 20(2), 1997, pp. 146-157
Authors:
ELLIOTT TE
MURRAY DM
OKEN MM
JOHNSON KM
BRAUN BL
ELLIOTT BA
POSTWHITE J
Citation: Te. Elliott et al., IMPROVING CANCER PAIN MANAGEMENT IN COMMUNITIES - MAIN RESULTS FROM ARANDOMIZED CONTROLLED TRIAL, Journal of pain and symptom management, 13(4), 1997, pp. 191-203
Authors:
OKEN MM
Citation: Mm. Oken, MULTIPLE-MYELOMA - PROGNOSIS AND STANDARD TREATMENT, Cancer investigation, 15(1), 1997, pp. 57-64
Authors:
OKEN MM
HARRINGTON DP
ABRAMSON N
KYLE RA
KNOSPE W
GLICK JH
Citation: Mm. Oken et al., COMPARISON OF MELPHALAN AND PREDNISONE WITH VINCRISTINE, CARMUSTINE, MELPHALAN, CYCLOPHOSPHAMIDE, AND PREDNISONE IN THE TREATMENT OF MULTIPLE-MYELOMA - RESULTS OF EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY E2479, Cancer, 79(8), 1997, pp. 1561-1567
Authors:
WIRT DP
GILES FJ
OKEN MM
SOLALCELIGNY P
BECK JR
Citation: Dp. Wirt et al., COST-EFFECTIVENESS OF INTERFERON-ALPHA ADDED TO CHEMOTHERAPY FOR HIGHTUMOR BURDEN FOLLICULAR NON-HODGKINS-LYMPHOMA, Blood, 90(10), 1997, pp. 843-843
Authors:
GREIPP PR
LEONG T
KAY NE
VANNESS BG
OKEN MM
KYLE RA
Citation: Pr. Greipp et al., FROM ECOG MYELOMA TRIAL E9486 - A PROGNOSTIC INDEX BASED ON TUMOR BURDEN, PROLIFERATION AND HOST IMMUNE STATUS, Blood, 90(10), 1997, pp. 1561-1561
Authors:
KAY NE
BONE N
LEONG T
OKEN MM
KYLE RA
VANNESS B
GREIPP PR
Citation: Ne. Kay et al., SEQUENTIAL PHENOTYPIC ANALYSIS OF BLOOD IMMUNE CELLS IN MYELOMA PATIENTS TREATED ON ECOG PROTOCOL E9486 - RELATIONSHIP OF IMMUNE CELLS TO TREATMENT AND CLINICAL OUTCOME, Blood, 90(10), 1997, pp. 1595-1595
Authors:
KAY NE
LEONG T
KYLE RA
GREIPP P
BILLADEAU D
VANNESS B
BONE N
OKEN MM
Citation: Ne. Kay et al., CIRCULATING BLOOD B-CELLS IN MULTIPLE-MYELOMA - ANALYSIS AND RELATIONSHIP TO CIRCULATING CLONAL CELLS AND CLINICAL-PARAMETERS IN A COHORT OF PATIENTS ENTERED ON THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP PHASE-IIIE9486 CLINICAL-TRIAL, Blood, 90(1), 1997, pp. 340-345
Authors:
VLOCK DR
ANDERSEN J
KALISH LA
JOHNSON JT
KIRKWOOD JM
WHITESIDE T
HERBERMAN RB
ADAMS GS
OKEN MM
HASELOW RE
Citation: Dr. Vlock et al., PHASE-II TRIAL OF INTERFERON-ALPHA IN LOCALLY RECURRENT OR METASTATICSQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - IMMUNOLOGICAL AND CLINICAL CORRELATES, Journal of immunotherapy with emphasis on tumor immunology, 19(6), 1996, pp. 433-442
Authors:
OKEN MM
KYLE RA
GREIPP PR
KAY NE
TSIATIS A
GREGORY SA
SPIEGEL RJ
OCONNELL MJ
Citation: Mm. Oken et al., COMPLETE REMISSION INDUCTION WITH COMBINED VBMCP CHEMOTHERAPY AND INTERFERON (RIFN(ALPHA-2B)) IN PATIENTS WITH MULTIPLE-MYELOMA, Leukemia & lymphoma, 20(5-6), 1996, pp. 447-452
Authors:
ROTHENBERG ML
MOORE MJ
CRIPPS MC
ANDERSEN JS
PORTENOY RK
BURRIS HA
GREEN MR
TARASSOFF PG
BROWN TD
CASPER ES
STORNIOLO AM
VONHOFF DD
ALBERTS DS
WOLFF R
KELSEN DP
KOCHA W
HALLER DG
MODIANOREVAH M
MOORE M
OKEN MM
SCHILSKY RL
SHAH A
Citation: Ml. Rothenberg et al., A PHASE-II TRIAL OF GEMCITABINE IN PATIENTS WITH 5-FU-REFRACTORY PANCREAS CANCER, Annals of oncology, 7(4), 1996, pp. 347-353
Authors:
GALE RP
HOROWITZ MM
REES JKH
GRAY RG
OKEN MM
ESTEY EH
KIM KM
ZHANG MJ
ASH RC
ATKINSON K
CHAMPLIN RE
DICKE KA
GAJEWSKI JL
GOLDMAN JM
HELBIG W
HENSLEEDOWNEY PJ
HINTERBERGER W
JACOBSEN N
KEATING A
KLEIN JP
MARMONT AM
PRENTICE HG
REIFFERS J
RIMM AA
ROWLINGS PA
SOBOCINSKI KA
SPECK B
WINGARD JR
BORTIN MM
Citation: Rp. Gale et al., CHEMOTHERAPY VERSUS TRANSPLANTS FOR ACUTE MYELOGENOUS LEUKEMIA IN 2NDREMISSION, Leukemia, 10(1), 1996, pp. 13-19
Authors:
WITTE RS
HSIEH P
ELSON P
OKEN MM
TRUMP DL
Citation: Rs. Witte et al., A PHASE-II TRIAL OF AMONAFIDE, CARACEMIDE, AND HOMOHARRINGTONINE IN THE TREATMENT OF PATIENTS WITH ADVANCED RENAL-CELL CANCER, Investigational new drugs, 14(4), 1996, pp. 409-413
Authors:
LIU PC
LEONG T
QUAM L
BILLADEAU D
KAY NE
GREIPP P
KYLE RA
OKEN MM
VANNESS B
Citation: Pc. Liu et al., ACTIVATING MUTATIONS OF N-RAS AND K-RAS IN MULTIPLE-MYELOMA SHOW DIFFERENT CLINICAL ASSOCIATIONS - ANALYSIS OF THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP PHASE-III TRIAL, Blood, 88(7), 1996, pp. 2699-2706
Authors:
TRENDLE MC
LEONG T
KYLE RA
OKEN MM
KAY NE
VANNESS B
GREIPP PR
Citation: Mc. Trendle et al., HYPODIPLOID MYELOMA REVISITED - RESPONSE TO THERAPY AND SURVIVAL IN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY E9486, Blood, 88(10), 1996, pp. 1549-1549
Authors:
KAY NE
BONE N
LEONG T
OKEN MM
KYLE RA
VANNESS B
GREIPP PR
Citation: Ne. Kay et al., T-HELPER PHENOTYPES IN THE BLOOD OF MYELOMA PATIENTS - ANALYSIS BY TREATMENT STATUS AND WITH CLINICAL-PARAMETERS, Blood, 88(10), 1996, pp. 1557-1557
Authors:
WINTER JN
ANDERSEN J
VARIAKOJIS D
GORDON LI
FISHER RI
OKEN MM
NEIMAN RS
JIANG SW
BAUER KD
Citation: Jn. Winter et al., PROGNOSTIC IMPLICATIONS OF PLOIDY AND PROLIFERATIVE ACTIVITY IN THE DIFFUSE, AGGRESSIVE NON-HODGKINS-LYMPHOMAS, Blood, 88(10), 1996, pp. 3919-3925
Authors:
OKEN MM
POMEROY C
WEISDORF D
BENNETT JM
Citation: Mm. Oken et al., PROPHYLACTIC ANTIBIOTICS FOR THE PREVENTION OF EARLY INFECTION IN MULTIPLE-MYELOMA, The American journal of medicine, 100(6), 1996, pp. 624-628